Genetic test for Herceptin candidate enters the US
This article was originally published in Clinica
Executive Summary
Abbott Laboratories has become the first company to gain US approval to market a genetic test for selecting breast cancer patients who are most likely to respond to therapy with the drug Herceptin. The only other tests with FDA approval for the same indication are immunohistochemistry-based assays, which Abbott claims are less accurate than the gene-based approach.